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Cardiovascular complications of 
chemotherapy:  A synopsis
progressive; and late-onset chronic progressive.(1,2) Acute cardio-
toxicity is rare. It occurs immediately after infusion of the 
anthracycline and manifests as a transient acute decline in LV 
function which is usually reversible.(3)
The early-onset chronic progressive form occurs in patients during 
therapy or within the first year of therapy.(3) 
Late-onset chronic progressive anthracycline-induced cardiotox-
icity occurs at least 1 year after completion of therapy. Early and 
late-onset chronic progressive cardiotoxicity typically presents as a 
CMO in adults which can progress to heart failure.(2) Cardiotoxicity 
may only become clinically evident 10 to 20 years after the first 
dose of chemotherapy. 
The risk of cardiotoxicity increases with cumulative doses of anthra-
cyclines. The cumulative dose of doxorubicin above which cardio-
toxicity occurs is >400mg/m2.(3,4,5) For this reason the maximum 
lifetime cumulative dose of doxorubicin is 400 to 550mg/m2.(3) 
Epirubicin or idarubicin appear to have less incidence of HF.(6,7) 
Apart from the cumulative dose, the risk factors for anthracycline 
toxicity include: intravenous bolus administration; higher single 
doses; history of prior irradiation; the concomitant use of other 
agents such as cyclophosphamide; trastuzumab and paclitaxel 
(known to have cardiotoxic effects); female gender; pre-existing 
cardiovascular disease; age (both young and old); and increased 
length of time since anthracycline completion.(1,2)
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Cancer treatment frequently entails the combined use of chemo-
therapy, radiotherapy and surgery to prolong life and provide a 
cure. Both chemotherapy and radiotherapy have the potential to 
cause acute or long term cardiovascular complications. The cardio-
vascular complications of chemotherapy include heart failure, 
myocardial ischaemia or infarction, thromboembolism, hyper-
tension and arrhythmias. This article reviews the incidence and 
effects of the various forms of cardiotoxicity caused by both the 
older and more recent chemotherapeutic agents currently used to 
treat cancer. 
LEFT VENTRICULAR (LV) DYSFUNCTION
Many chemotherapeutic agents have been linked to the develop-
ment of left ventricular dysfunction (LVD) (Table 1) and/or heart 
failure (HF). The cumulative dose, administration schedule and 
concomitant use of other cardiotoxic therapies determine the 
likelihood of cardiomyopathy (CMO).
Anthracyclines
The anthracycline class of agents is commonly used in the 
management of a variety of malignancies, most frequently as adju-
vant therapy for breast cancer and as systemic treatment of 
sarcomas, lymphomas and leukaemias. Formal estimates of the 
worldwide prevalence of anthracycline cardiotoxicity are lacking. 
Differences among paediatric, adult and elderly populations and 
the lack of universal criteria for detecting and reporting cardiac 
events make such estimates even more challenging. Anthracycline 
cardiotoxicity has been classified into acute; early-onset; chronic; 
It is important to identify chemotherapy-related cardio-
toxicity as it may impact on the overall survival of cancer 
patients. The various forms of cardiotoxicity encountered 
during and after chemotherapy for cancer, include impaired 
left ventricular function leading to cardiomyopathy (CMO), 
myocardial ischaemia, hypertension (HTN), thromboembolic 
states, bradycardia and prolongation of the QT interval 
predisposing to ventricular arrhythmias. The relationships 
between specifi c chemotherapeutic agents and the occurrence 
of these complications are discussed, highlighting the need for 


















Antibody-based tyrosine kinase inhibitors
Both trastuzumab and bevacizumab are monoclonal antibodies 
used as targeted oncologic therapies in a variety of malignancies. 
Approximately 15% of all breast cancers over-express the cell 
surface receptor Her2. This group is characterised by aggressive 
tumour behaviour and a worse prognosis. The presence of the 
Her2 serves as a target for biologic therapies. Use of the humanised 
monoclonal antibody trastuzumab (Herceptin) directed against 
the Her2 receptor has revolutionised the treatment of Her2-
positive breast cancer. Adjuvant phase 3 trials of trastuzumab 
have demonstrated a 50% reduction in recurrence of disease and 
a 33% improvement in survival. 
Bevacizumab (Avastin), a humanised monoclonal antibody directed 
against Vascular Endothelial Growth Factor (VEGF), has significant 
anti-tumour activity when combined with chemotherapy and has 
been approved for use in several types of advanced solid tumours 
including breast, lung, colorectal and renal carcinomas.(8)
TABLE 1: Chemotherapeutic agents associated with the development of Left Ventricular Dysfunction (LVD) and Heart Failure (HF).












Antibody-based tyrosine kinase inhibitors
Bevacizumab(8)
Trastuzumab(9-11)


















Acute   <1%
Up to 26%
Early chronic progressive 
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Late chronic progressive 
1.6-5%























Use with other agents
Mediastinal radiation
Not dose dependent
Age > 50 yrs























When trastuzumab is used as monotherapy the incidence of cardiac 
dysfunction ranges from 2% to 7% but rises to 27% when used 
concurrently with anthracyclines.(9-11) Risk factors for CMO with this 
agent include: age >50yrs; borderline EF before treatment; history 
of cardiovascular disease; the sequence in which chemotherapy is 
administered; and prior treatment with anthracyclines.(9-11)
Regimens either avoiding anthracyclines or temporally separating 
anthracycline and trastuzumab, including BCIRG 006(12) (a Phase 3 
randomised study evaluated the use of docetaxel and carboplatin 
combined with Herceptin following initial adjuvant treatment with 
doxorubicin and cyclophosphamide chemotherapy for early stage 2 
Her2-positive breast cancer) and HERA(13) (a multicentre ran-
domised trial comparing 1 or 2 years of trastuzumab treatment 
after standard chemotherapy), have reported the lowest rates of 
significant cardiac dysfunction. In contrast to anthracycline-medi-
cated toxicity, which tends to be dose dependent and irreversible, 
trastuzumab-related cardiotoxicity generally is not dose dependent 
nor associated with structural changes on biopsy and tends to be 
reversible. The majority of patients recover though typically con-
tinue using cardiac medications. 
Alkylating agents
Cardiotoxicity has been associated with cyclophosphamide 
therapy.(14) Patients may present with pericardial effusions, HF 
or myopericarditis. The risk of cardiotoxicity appears to be dose 
related (>150mg/kg and 1.5g/m2/day) and occurs within 1 to 10 
days after the administration of the first dose. Other risk factors 
include prior anthracycline or mitoxantrone therapy and mediastinal 
radiation.(6)
Another alkylating agent ifosfamide may also be responsible for 
cardiotoxicity when used in combination with other agents.(9) Acute 
onset of HF occurred within 6 to 23 days after the first dose and a 
dose response trend was observed (doses >12.5g/m2).(15)
Other agents
A host of other chemotherapeutic agents can cause LVD including 
anti-metabolites such as clofaribine which may cause transient LVD 
in paediatric patients treated for acute lymphoblastic leukaemia.(6-7) 
The proteasome inhibitor bortezomib used in the treatment of 
multiple myeloma can also cause LVD.(16)
The small molecule tyrosine kinase inhibitors such as dasatinib(17) 
used in the treatment of leukaemia, lapatinib(18) approved for the 
treatment of trastuzumab-resistant breast cancer and sunitinib(19) 
used in stromal tumours and renal carcinoma have all been 
implicated in causing LVD. CMO related to sunitinib may not be 
reversible.
Diagnosis of Left Ventricular Dysfunction (LVD) and 
Heart Failure (HF)
The diagnosis of HF is established by combining the clinical his-
tory, examination, electrocardiogram, chest radiography, labora-
tory tests and non-invasive imaging.(20) Biochemical markers such 
as troponin I(21) and B-type natriuretic peptide(22) may detect 
myocardial injury before changes in LVEF become apparent. 
Echocardiography with speckle tracking could be the most sensi-
tive method of detecting early cardiac dysfunction.(23) The regular 
monitoring of cardiac function during treatment is important and 
algorithms have been developed for serial monitoring of LV 
ejection fraction.(24)
Prevention of LVD and HF
The most significant factor for anthracycline-induced CMO is the 
cumulative dose the patient has received and therefore prevention 
necessitates minimizing the patient’s lifetime cumulative dose. 
Other preventive measures include altering the method of admi-
nistration (continuous vs. bolus), use of anthracycline analogues and 
the addition of cardioprotectants such as dexrazoxane.(3-5) 
Treatment of LVD and HF
As there are no specific HF guidelines for cancer patients the usual 
recommendations should be followed. Risk factor management 
by controlling hypertension, diabetes and hyperlipidaemia are 
important. Patients with anthracycline-induced cardiotoxicity may 
improve on treatment but complete resolution of the under-
lying process is uncommon and cardiac transplantation may be 
required.(25) Trastuzumab should be discontinued when HF 
develops. Cardiac function generally recovers over an average of 
6 weeks. Trastuzumab may be resumed once LV function has 
improved provided that protective medication is given and the 
patient is closely monitored.(10)
To date 4 case series have evaluated the use of beta blockers in 
treatment of anthracycline-induced CMO and found to be bene-
ficial.(26) Carvedilol may have an advantage because of its anti-
oxidant properties.(27)
The classification of cardiotoxicity varies and is based on clinical 
radionuclide angiography and/or echocardiographic criteria. It can 
be classified as mild (a decrease in EF >10% from baseline with a 


















baseline with a final value of <50% and no symptoms or signs of 
heart failure); and severe (a decrease in EF of >10% from baseline 
with a final value of <50% and symptoms or signs of heart failure 
or a decrease in EF of any % leading to a final value of <40% irre-
spective of signs or symptoms of heart failure).(28,29) 
MYOCARDIAL ISCHAEMIA
Although cardiac ischaemia is uncommonly related to chemotherapy 
an increased risk of acute coronary syndromes has been associated 
with cytotoxic agents. Chest pain is common in cancer patients 
often necessitating a work-up to exclude myocardial ischaemia. 
Both radiotherapy and chemotherapy are associated with an 
increased risk of coronary artery disease and/or acute coronary 
syndromes (ACS).(30)
Fluorouracil (5-FU) an anti-metabolite is one of the best known 
chemotherapeutic agents causing angina. In rare cases myocardial 
infarction (MI), arrhythmias, HF, cardiogenic shock and sudden 
death have been reported.(30-31) 
Other chemotherapeutic agents including paclitaxel(32) and 
docetaxel(33) both anti-microtubular agents have also been 
associated with causing myocardial ischaemia and even infarction. 
Chemotherapy agents implicated in the development of myocardial 
ischaemia/infarction are shown in Table 2.
Treatment
Patients with ACS should be managed according to the usual 
guidelines. This may pose a problem in cancer patients because of 
thrombocytopaenia or recent surgery. In a retrospective study in 
patients with thrombocytopaenia, aspirin improved the outcome 
without increasing the risk of bleeding.(34) 
HYPERTENSION (HTN)
Hypertension and cancer are often found in the same patient. 
Epidemiological studies suggest that there is an association between 
the two and that HTN affects the overall prognosis of cancer 
patients. More recent chemotherapeutic agents such as the VEGF 
inhibitors disrupt angiogenesis thus making these patients sus-
ceptible to developing HTN.(35)
HTN is common in patients treated with bevacizumab. Most 
patients continue therapy and are adequately treated with anti-
hypertensives. Complications of bevacizumab-induced HTN have 
included hypertensive encephalopathy and brain haemorrhage.(8)
Other agents inducing HTN include sorafenib(36) and sunitinib.(37)
Table 3 shows the incidence of HTN associated with some anti-
cancer drugs.
Treatment of HTN
Standard anti-hypertensive therapy is indicated. Discontinuation of 
anti-angiogenic therapy causing HTN is controversial since the 
appearance of HTN seems to associate with a greater treatment 
response.(38) It may be beneficial to use ACE inhibitors as first line 
therapy due to their ability to prevent plasminogen activator 
inhibitor-1 expression.(39) Non-dihydropiridine calcium channel 
blockers such as diltiazem and verapamil should not be used in 
sorafenib-treated patients since they are both inhibitors of the 
CYP3A4 iso-enzyme.(40)
TABLE 2: Chemotherapeutic agents implicated in the development of myocardial ischaemia/infarction.
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Cancer predisposes to a prothrombotic state. The risk is highest in 
patients with metastatic cancer and in those with risk factors, 
including the use of central venous lines and associated co-
morbidities such as immobility, HF, atrial fibrillation, dehydration 
and administration of concurrent chemotherapy.(41,42,43) Some drugs 
that have been associated with a greater risk of thrombo-embolism 
include cisplatin(44) used in renal tract carcinomas, vorinostat(45) used 
in T-cell lymphoma and thalidomide(41,42) used for patients with 
myeloma. 
Table 4 shows the incidence of venous thromboembolism with 
selected agents.
BRADYCARDIA
A variety of circumstances may contribute to the development of 
bradycardia and heart block in cancer patients. The conduction 
system can be affected by fibrosis due to ageing, radiation therapy, 
amyloidosis or a primary cardiac tumour. Several chemotherapeutic 
agents most commonly paclitaxel and thalidomide may also cause 
heart block.(46)
Table 5 shows the incidence of heart block with selected agents.
QT PROLONGATION
The complications of QT interval prolongation including Torsade 
de Pointes are rare but can have life threatening consequences. 
Cancer patients may be particularly prone to QT prolongation 
since 16% to 36% of cancer patients have baseline ECG abnor-
malities.(47,48) Cancer patients may have co-morbid diseases including 
structural heart disease, renal or hepatic dysfunction, as well as 
using other medications that may themselves prolong the QT 
interval. Cancer patients may develop electrolyte abnormalities 
because of nausea, vomiting, diarrhoea and decreased oral intake 
further predisposing to QT prolongation.(47, 48) 
The incidence of QT prolongation with the use of Arsenic Trioxide 
ranges widely in the published literature from 25%-90%.(49) The QT 
prolongation potential of both of dasatinib(50) and lapatinib(51) has 
been reported. 
Table 6 shows the incidence of QT prolongation associated with 
some cancer drugs.
CONCLUSION
Chemotherapy is associated with a wide variety of adverse cardio-
vascular effects. Patients need to be carefully monitored during and 
after their cancer treatment. Many cancer patients are not receiving 
treatment consistent with heart failure guidelines.(52) A great 
opportunity exists for closer collaboration between cardiologists 
and oncologists to improve the care of cancer patients receiving 
cardiotoxic therapy.
Conflict of interest: none declared.
CHEMOTHERAPY-RELATED CARDIOTOXICITY
TABLE 3: Chemotherapeutic agents associated with the develop-
ment of hypertension.
             Agent Trade name      Incidence Malignancy  










Breast, lung, renal 
carcinoma
Renal and hepatic 
carcinoma
Renal carcinoma
TABLE 5: Chemotherapeutic agents associated with the develop-
ment of bradycardia/heart block.
             Agent Trade name      Incidence Malignancy  








Lung, head and 
neck, breast 
carcinomas
TABLE 4: Chemotherapeutic agents associated with thrombo-
embolism.
             Agent Trade name      Incidence Malignancy  















TABLE 6: Chemotherapeutic agents associated with QT 
prolongation.
             Agent Trade name      Incidence Malignancy  
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